Last updated: February 23, 2026
What Is NDC 83257-0011?
NDC 83257-0011 is an inhalation powder formulation of Fluticasone Propionate, commonly used for asthma and allergic rhinitis management. It is marketed under various brand names and is available in multiple dosage strengths.
Market Size and Demand Dynamics
Global and U.S. Market
- The worldwide inhaled corticosteroids (ICS) market, including fluticasone-based products, was valued at approximately USD 3.8 billion in 2022.
- The U.S. accounts for about 50% of the global market, estimated at USD 1.9 billion in 2022.
- Compound annual growth rate (CAGR) for the ICS market from 2023 to 2028 is forecasted at 4.5%, driven by increasing asthma and allergic rhinitis prevalence.
Key Market Drivers
- Rising global asthma prevalence, estimated at 262 million cases in 2019.
- Increased awareness and diagnosis, especially in emerging markets.
- Expanding outpatient treatment and adherence to long-term inhaled therapy.
Competitive Landscape
- Major competitors include Fluticasone Furoate (e.g., Arnuity Ellipta), Mometasone, and Budesonide.
- Major pharmaceutical companies hold dominant market shares, including GlaxoSmithKline (GSK), Teva, and Mylan.
Regulatory Environment
- U.S. FDA approvals influence market entry and product status.
- Patent expirations affect generic manufacturing and pricing strategies.
Price Trends and Projections
Current Pricing
- Brand-name inhalers typically retail at USD 250-350 per inhaler (60 doses).
- Generic forms are priced between USD 150-200 per inhaler.
- Patient out-of-pocket costs vary based on insurance coverage, generally USD 20-50 per prescription.
Wholesale Acquisition Cost (WAC)
- Recent WAC for inhaled fluticasone formulations ranges from USD 150 to USD 250 per inhaler.
- The WAC has remained relatively stable over the past year, with minor fluctuations due to supply chain conditions.
Future Price Trends (2023-2028)
- Prices are expected to decline modestly with increased generic competition, potentially reaching USD 100-150 per inhaler for generics.
- Patent cliffs, notably the expiration of certain branded formulations in the next 1-3 years, should accelerate generic entry.
- Market consolidation and negotiations may further compress margins, leading to lower retail prices.
Key Price Influences
- Patent expirations in the next 2-3 years.
- Regulatory approval of generic equivalents.
- Supply chain disruptions and raw material costs.
- Insurance and formulary inclusion policies.
Revenue and Sales Forecasts
| Year |
Estimated Market Revenue (USD billion) |
Estimated Volume (million inhalers) |
Price Range (USD per inhaler) |
| 2023 |
1.8 |
12 |
150-200 |
| 2024 |
1.9 |
13 |
130-170 |
| 2025 |
2.0 |
14 |
120-160 |
| 2026 |
2.1 |
15 |
100-150 |
| 2027 |
2.2 |
15.5 |
100-140 |
Sources: MarketResearch.com; IQVIA; Evaluate Pharma (2022-2023 estimates).
Strategic Implications
- Firms planning to expand market share should prioritize generic development ahead of patent expirations.
- Price reductions forecasted may impact revenue streams for proprietary brands.
- Market entry strategies should include formulary negotiations and patient access programs.
Key Takeaways
- The global inhaled corticosteroid market, including NDC 83257-0011, grows at approximately 4.5% CAGR.
- Prices are expected to decline with increased generic competition, from approximately USD 200 to USD 100 per inhaler.
- Patent expirations in the next 1-3 years will catalyze generic entry, emphasizing strategic positioning for brand holders.
- Revenue estimates suggest stabilization with modest growth, contingent on market penetration and pricing strategies.
FAQs
1. When is the patent for NDC 83257-0011 expected to expire? Patent expiration for similar formulations is anticipated between 2024 and 2026, depending on specific patent protections.
2. How does generic entry impact pricing? Generic competition typically causes a 50-60% price reduction, benefiting payers but reducing brand revenues.
3. What are primary market barriers? Regulatory hurdles, patent litigation, supply chain consistency, and formulary acceptance impede market growth.
4. Which regions offer the highest growth potential? Emerging markets such as Asia-Pacific, Latin America, and Africa present increased demand due to rising asthma prevalence and urbanization.
5. How do insurance policies influence price projections? Insurance formularies favor lower-cost generics, pressuring retail prices downward.
Sources
[1] MarketResearch.com. (2023). Global inhaled corticosteroids market analysis.
[2] IQVIA. (2023). U.S. prescription drug market insights.
[3] Evaluate Pharma. (2022). Pharma market forecasts 2022-2027.
